Eris Lifesciences liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.25×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.74×	0.74×	0.91×	0.91×	1.73×
0.53×	0.53×	0.67×	0.83×	1.43×
238	54.7	205	94.2	86.0
−880	−537	−119	−230	321

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ERIS₹1,163.60

Eris Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersMANKIND AJANTPHARM TORNTPHARM EMCURE GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹16,116 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.25
Current Ratio	1.73	0.91	0.91	0.74	0.74
Quick Ratio	1.43	0.83	0.67	0.53	0.53
Cash, Equiv & ST Investments	86.0	94.2	204.7	54.7	238.1
Working Capital	321.5	-230.0	-118.9	-537.3	-880.3

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.